(Bloomberg) — Bearish investors are holding on to their short bets on Moderna Inc. even as the biotech’s market value swelled by more than $25 billion this year on optimism its experimental messenger-RNA vaccine will play a part in tamping down the pandemic.Options data suggest the stock is ready for another double-digit swing over the next few weeks and with S3 Partners data showing about $1.84 billion shares shorted, bears might face fresh pain or finally claw back some losses.Moderna “was and is now a short squeeze candidate,” Ihor Dusaniwsky, S3’s managing director of predictive analytics, said in an interview.The …read more
Source:: Yahoo Finance
